Weiss Ratings restated their sell (e+) rating on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a research report report published on Friday,Weiss Ratings reports.
TherapeuticsMD Trading Down 1.5%
NASDAQ TXMD opened at $1.29 on Friday. TherapeuticsMD has a 12 month low of $0.70 and a 12 month high of $2.44. The stock has a market cap of $14.93 million, a price-to-earnings ratio of -21.50 and a beta of 0.58. The company’s 50 day moving average is $1.10 and its two-hundred day moving average is $1.17.
TherapeuticsMD (NASDAQ:TXMD – Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported $0.05 EPS for the quarter. The company had revenue of $0.95 million for the quarter. TherapeuticsMD had a negative net margin of 17.94% and a negative return on equity of 2.01%.
About TherapeuticsMD
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- What Are the FAANG Stocks and Are They Good Investments?
- PulteGroup Is Down But Not Out—Here’s What Wall Street Missed
- Stock Splits, Do They Really Impact Investors?
- Cleveland-Cliffs Breaks to New Highs on Earnings, More Upside?
- Top Stocks Investing in 5G Technology
- Is Landstar the Next Big Winner in Transportation Stocks?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
